COVID-19 Vaccines and Ivermectin with MedCram and Dr. Roger Seheult

In a systematic meta-analysis of ivermectin clinical trials for COVID-19, the only consistent finding across studies was a reduction in time to negative PCR (faster viral clearance).

"sticking to just the scientific literature, you know, even that systematic meta-analysis that Dr. Seheult mentioned, you know, if you look at all the different studies, and a lot of them were preprints that they included, the only real consistent finding that was found, and consistent meaning every study showed it was time was basically time to a negative PCR. In other words, ivermectin and ivermectin plus the kitchen sink or ivermectin plus whatever, it seemed to lead to a faster viral clearance to some degree." (said at 1:33:45)

Comprehensive systematic reviews and meta-analyses of randomized controlled trials (RCTs) evaluating ivermectin for COVID-19 do not find a consistent reduction in time to negative PCR or faster viral clearance across studies. Several systematic reviews, including those published in Clinical Infectious Diseases and the QJM, found no significant difference in viral clearance or time to negative PCR between ivermectin and control groups, directly refuting the claim that faster viral clearance was consistently shown across every study.

contradicts: Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-ana… (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022) · cited 124x in the literature
"AEs, SAEs, and viral clearance were similar between IVM and control groups (low QoE for all outcomes)... Compared with the standard of care or placebo, IVM did not reduce all-cause mortality, LOS, or viral clearance in RCTs in patients with mostly mild COVID-19." (abstract, results and conclusions)
pubmed full study (doi)
contradicts: Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and m… (QJM : monthly journal of the Association of Physicians 2021) · cited 40x in the literature
"Based on meta-analysis of RCTs, the use of ivermectin was not associated with reduction in time to viral clearance, duration of hospitalization, incidence of mortality and incidence of mechanical ventilation." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. … (Journal of clinical epidemiology 2022) · cited 31x in the literature
"moderate certainty evidence shows that it probably does not increase symptom resolution or improvement (RD 14 more per 1000) nor viral clearance (RD 12 fewer per 1000)." (abstract, results, passage verified)
pubmed full study (doi)

2:14:47 Rhonda Patrickcontradictedhigh

In 2014, the first clinical trial using an mRNA vaccine as immunotherapy for cancer in humans was conducted.

"In 2014, there's the first mRNA vaccine in terms of immunotherapy for cancer, so trying to treat cancer with mRNA vaccines. These are all in humans." (said at 2:14:47)

Clinical trials evaluating mRNA vaccines as cancer immunotherapy in humans were conducted and published years before 2014. For example, a phase I/II clinical trial evaluating direct intradermal injection of autologous tumor-derived mRNA in 15 metastatic melanoma patients was published in 2008 (Weide et al.), and a subsequent phase I/II trial using protamine-stabilized mRNA encoding tumor antigens was published in 2009. While clinical development of personalized neoantigen mRNA cancer vaccines expanded significantly around 2014, the first human trials of mRNA cancer vaccines date back to the 2000s.

contradicts: Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. (Journal of immunotherapy (Hagerstown, Md. : 1997) 2008) · cited 262x in the literature
"We used this protocol to vaccinate 15 melanoma patients. For each patient a growing metastasis was removed, total RNA was extracted, reverse-transcribed, amplified, and cloned. Libraries of cDNA were transcribed to produce unlimited amounts of copy mRNA. Autologous preparations were applied intradermally in combination with granulocyte macrophage colony-stimulating factor as adjuvant. We demonstrate here that such treatment is feasible and safe (phase 1 criteria)." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in … (Journal of immunotherapy (Hagerstown, Md. : 1997) 2009) · cited 384x in the literature
"We injected intradermally protamine-stabilized mRNAs coding for Melan-A, Tyrosinase, gp100, Mage-A1, Mage-A3, and Survivin in 21 metastatic melanoma patients." (abstract, results, passage verified)
pubmed full study (doi)

COVID-19 Vaccines and Ivermectin with MedCram and Dr. Roger Seheult

Contradicted by research

In a systematic meta-analysis of ivermectin clinical trials for COVID-19, the only consistent finding across studies was a reduction in time to negative PCR (faster viral clearance).

In 2014, the first clinical trial using an mRNA vaccine as immunotherapy for cancer in humans was conducted.